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Resistance emerging after ceftazidime or cefepime therapy was investigated in a
peritonitis model. Mice were given a peritoneal challenge (10* cfu plus talcum) and
treated by either antibiotic (50 mg/kg/dose, which produced similar antibiotic
concentrations in peritoneal fluid in both cases). After one or three doses, resistance
never developed in Serratia marcescens or Citrobacter freiouiii infections. After
Enterobacter cloacae and Pseudomonas aeruginosa challenge, ceftazidime selected
more resistance (21/36 cases) than did cefepime (1/36 cases). In mice challenged with
resistant strains selected by ceftazidime therapy, cefepime (six doses) successfully
treated 7/18 E. cloacae infections but 0/18 P. aeruginosa infections; ceftazidime was
never effective. Neither cefepime nor ceftazidime cured mice infected with the
resistant strain selected by cefepime. MICs were poor predictors of further emer-
gence of resistance in mice inoculated with strains classified as susceptible, but
antibiotic-containing agar gradients plated with a high inoculum (10* cfu) allowed
better prediction. In selected clinical situations, cefepime may be preferable because
it may be associated with less frequent emergence of resistance.
Introduction
Development of bacterial resistance during a therapy with third generation cephalo
sporins such as cefotaxime and ceftazidime has been repeatedly documented (Pechere,
1989) and is of concern in hospital practice. It is a particular problem in infections
caused by Enterobacter cloacae or Pseudomonas aeruginosa (King et al., 1983; Quinn,
Di Vicenzo & Foster, 1987). Recently, other cephalosporins have been developed,
aimed at limiting this problem. Cefepime is one of these recent /Mactam drugs, showing
poor affinities for /Mactamases combined with stability to enzymatic hydrolysis (Phelps
et al., 1986; Hiraoka et al., 1988; Bellido, Pechere & Hancock, 1991) and maintaining
in-vitro activity against ceftazidime and cefotaxime resistant strains belonging to the
genera Enterobacter, Pseudomonas and Citrobacter (Vuye & Pick, 1985; Fung-Tome et
al., 1989).
In order to evaluate the risk of resistance arising during antibiotic therapy, a murine
model has been developed (Pechere et al., 1986; Marehou et al., 1987*). In this model,
emergence of resistance depended on the bacterial species inoculated in the animal and
on the compound administered. Resistance was seen more often with E. cloacae
followed by P. aeruginosa and Serratia marcescens. A greater risk of resistance was
associated with therapy by third generation cephalosporins (cefotaxime, ceftriaxone,
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ceftazidime) followed by monobactams (carumonam, aztreonam), while resistance
during imipcnem therapy was uncommon and limited to P. aeruginosa. With a similar
model, we have examined the phenomenon of resistance acquired during therapy with
cefepime in comparison with ceftazidime, as well as the relevant virulence capabilities
of resistant strains obtained in the model.
Methods
Bacteria
The bacterial strains used in this study were clinical isolates. E. cloacae 218S and 219S
were isolated from cerebrospinal fluid in patients with purulent meningitis (Eng et al.,
1987). S. marcescens 239 and 240, C.freunaHi 151 and 158 were strains isolated in blood
cultures from patients not treated with /Mactam agents before the blood sampling.
P. aeruginosa 302S and 305S were isolated from infected wounds (Michea-Hamzeh-
pour et al., 1987).
Antibiotics
Cefepime, (sulphate salt), was provided by Bristol-Myers-Squibb, Syracuse, NY, USA;
ceftazidime was obtained from Glaxo AG, Bern, Switzerland. Working solutions were
freshly prepared from powders of known potency according to the recommendations of
the manufacturer.
Growth-inhibitory activity
MICs were determined by two methods. The first was an agar dilution method
(National Committee for Clinical Laboratory Standards, 1985). The inoculum
contained c. 104 cfu per spot. The second method used antibiotic gradient containing
plates, as described previously (Marchou et al., 1987a). The inoculum was c. 10* per
dish. This method allowed the definition of two levels of antibiotic activity. The first
level was read as the boundary concentration, the boundary being the relatively sharp
limit separating the confluent growth at lower antibiotic concentrations from the zone
of higher antibiotic concentrations, where only single colonies grew. The second level of
antibiotic activity, called no-growth concentration, was the minimal concentration
inhibiting all visible growth.
Antibiotic resistance acquired in vivo
Swiss ICR female mice, weighing 20-30 g, were conditioned for one week after receipt
from the breeder and kept in conventional cages with free access to water and
antibiotic-free chow. Inoculum was prepared from an overnight broth culture and
diluted with 0-9% NaCl. One mL of the diluted culture, containing approximately
10* cfu, and 125 mg of sterile talcum (magnesium hydropolysilicate), was injected
intraperitoneaUy to establish peritonitis. Talcum was used as a foreign body in order to
ascertain lethal sepsis in all cases. Two hours after bacterial challenge the antibiotic
therapy started, with the administration of subcutaneous doses of 50 mg/kg of cefe-
pime or ceftazidime. Three therapeutic schedules were used: single dose, three doses
(dosing intervals: 2 h) or six doses (dosing intervals: 2 h). Analysis of the peritoneal
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bacterial population was performed by sampling the peritoneal fluid at various time
intervals with a syringe and needle. Mice were killed by cervical dislocation 24 h after
inoculation. The peritoneal fluid was plated after appropriate dilutions on antibiotic-
free agar for colony counts, whereas the rest of the sample was placed into antibiotic-
free broth to allow overnight growth for further susceptibility testing. Data were
compared from treated and untreated control animals. At autopsy, heart blood and
spleen pulp were sampled for viable counts after careful local heat-searing of the organ
surface, followed by collection with syringe and needle. A significant shift to resistance
was defined as an increase of the boundary concentration by at least four-fold.
Antibiotic assays
Mice were injected intraperitoneally with 1 mL of 0-9% NaCl, containing 250 mg of
sterile talcum. Two hours later, antibiotics were administered subcutaneously,
50 mg/kg. Mice were killed by cervical dislocation (three or four animals per time
interval), peritoneal exudate was sampled and deposited on 6-5 mm paper discs. Assays
were performed by using a disc-diffusion method, with Mueller-Hinton agar and
Staphylococcus aureus as the test organism.
Virulence assay
Using groups of five mice over an inoculum range of approximately 10' to 109 cfu (i.e.
25-30 animals for each strain studied), the virulence of initial and post-therapy strains
injected intraperitoneally was estimated after determination of the inoculum able to kill
50% of the animals inoculated (LD^).
Results
Susceptibility testing before therapy
Before therapeutic exposure, the eight strains used in the study were susceptible to both
cefepime and ceftazidime (Table I). As judged by MICs in agar dilution, and on a
weight basis, cefepime was more potent than ceftazidime against E. cloacae,
S. marcescens and Citrobacter freundii, but ceftazidime was more active against
P. aeruginosa. MICs, as measured by agar dilution, were very similar to the boundary
concentrations as determined on antibiotic-containing agar. On gradient plates, no-
growth concentrations were in the same range (a difference of four-fold or less) as the
corresponding boundary concentration for both cefepime and ceftazidime in
S. marcescens and C. freundii, and for cefepime only in E. cloacae and P. aeruginosa.
In the two latter species, no-growth concentrations were higher than boundary concen-
trations by ten- to 150-fold when ceftazidime was tested, and overall, no-growth
concentrations were higher for ceftazidime than for cefepime.
Antibiotic assays
Ceftazidime and cefepime displayed similar pharmacokinetic profiles in the peritoneal
fluid, with antibiotic concentrations far above the MICs of initial strains 60 and
120 min after a 50 mg/kg dosing (Table II).
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Table L Growth inhibitory activity of cefepime and ceftazidime before therapeutic exposure
Strain
E. cloacae 218S
E. cloacae 219S
5. marcescens 239
S. marcescens 240
C. freundii 151
C. freundii 158
P. aeruginosa 3O2S
P.aeruginosa 3O5S
Antibiotic
cefepime
ceftazidime
cefepime
ceftazidime
cefepime
ceftazidime
cefepime
ceftazidime
cefepime
ceftazidime
cefepime
ceftazidime
cefepime
ceftazidime
cefepime
ceftazidime
Growth
MIC
006
0-25
006
0-25
1-6
4
0O6
0-12
006
04
O06
025
1
05
2
2
inhibitory concentrations (mg/L)
boundary*
004
024
004
020
1-5
30
005
012
O03
03
003
024
2-5
1-5
6
1-5
no-growth
0125
20
020
32
2-5
6
015
1
008
05
006
05
5
30
6
15
"As measured by agar dilution (inoculum: c 104 cfu per spot); * as measured on antibiotic gradient
containing agar (inoculum: c. 10* cfu per dish).
Emergence of resistance after a first therapeutic exposure
Thirty-two untreated mice, serving as controls (four per strain) were killed and
autopsied 24 h after inoculation challenge. Severe peritonitis was observed in all cases,
and the peritoneal fluid contained from 91 x 10' to 7 x 1010 cfu/mL (all bacterial strains
being considered), when the inoculum used for challenging the animals was
1-6 ±3-5 x 10* cfu/mL. Autopsy of control mice also showed enlarged spleens which
yielded growth of the pathogen inoculated in all cases. Blood cultures were positive in
90% of the cases. One hundred and forty-four mice were treated by cefepime or
ceftazidime, one or three doses of SO mg/kg each (Table III). Resistance did not
develop in any mouse infected with S. marcescens or C. freundii. In mice infected with
E. cloacae or P. aeruginosa, resistance commonly occurred after ceftazidime therapy
with either the one or three dose regimens; with cefepime resistance developed in only a
Table II. Antibiotic concentration in peritoneal fluid after subcutaneous administration of
cefepime or ceftazidime in mice with aseptic peritonitis
Antibiotic administered
(dosing)
Ceftazidime
(50 mg/kg)
Cefepime
(50 mg/kg)
Time (min)
after dosing
30
60
120
180
60
120
180
Antibiotic concentration (mgL)
in peritoneal fluid'
64-6
57-8
13-0
<2-5
38-2
12-9
3-3
•Mean of three or four mice.
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Table IIL Resistance emerging after therapy with cefepime or ceftazidime, one or three doses
(50mg/kg)
Strain Therapy
Number of mice with acquired resistance
(fold increase of boundary concentration)
after one dose* After three doses*
E. cloacae 218
E. cloacae 219
S. marcescens 239
S. marcescens 240
C.freundU 151
C.frewtdii 158
P. aeruginosa 302
P. aeruginosa 305
cefepime
ceftazidime
cefepime
ceftazidime
cefepime
ceftazidime
cefepime
ceftazidime
cefepime
ceftazidime
cefepime
ceftazidime
cefepime
ceftazidime
cefepime
ceftazidime
"Out of six mice inoculated.
*Out of three mice inoculated.
0
3 (125-200)
0
5(250-640)
0
0
0
0
0
0
0
0
0
2(8)
0
2(8)
0
3(80)
1(50)
3 ( > 320)
0
0
0
0
0
0
0
0
0
2(20)
0
1(17
single mouse infected with E. cloacae 219S and dosed three times (Table 111).
Chi-square statistics, after Yates* correction, indicated that in E. cloacae infected mice
receiving a single antibiotic dose, resistance was significantly more frequent after
ceftazidime than after cefepime therapy (P < 001). When resistance emerged, MIC
increases were impressive (at least 80-fold) in E. cloacae infections, and more limited
(eight-fold) in P. aeruginosa infections. As to the peritoneal viable counts, an antibiotic
effect was observed in all cases, i.e. a decrease of at least two logs compared to parallel
counts in the corresponding untreated mice. Twenty-four hours after challenge, treated
animals had 2-3 to over 6 logs lower counts than did untreated animals, even when
resistance occurred. For four of the strains under study, peritoneal viable counts were
determined over 24 h in animals receiving three antibiotic doses or no antibiotic
(controls) (Figure 1). Within the first 8 h following bacterial challenge, these counts
were indistinguishable whether cefepime or ceftazidime was administered; after 24 h,
viable counts remained similar in three experiments, while cefepime therapy was
associated with a lower peritoneal cfu count in E. cloacae 219S (Figure 1) where
resistance emerged after ceftazidime therapy.
Prediction of emergence of resistance in vitro
The eight strains exposed to cefepime or ceftazidime therapy were initially classified as
susceptible to these antibiotics according to standard MIC determination, but resist-
ance emerged in some of the animals treated. So we tried to find other in-vitro
parameters which would be able to ensure a better prediction of the therapeutic
outcome in the model. Higher no-growth concentration on antibiotic-containing
gradient agar was associated with greater risk of resistance in vivo, except in the
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Figure 1. Viable counts of peritoneal bacteria in treated and untreated control mice after peritoneal
challenge with 10* cfii. (a) E. cloacae 218S; (b) E. cloacae 219S; (c) C.freunOi 151; (d) P. aeruginosa 302S.
+ , No treatment; A, ceftazidime; • , cefephne.
cefepime-treated mouse infected with E. cloacae 219S where resistance emerged
(Table II) despite low no-growth concentration (Table I). A greater correlation was
found with the ratio of no-growth concentration to the boundary concentration versus
the number of mice in which resistance developed (Figure 2).
256
3 4 5 6 7 8
Number of mice with resittance
Flgare 2. Correlation of emergence of resistance in mice with resistance as judged by cefepime- or
ceftaTklimr-gradient containing agtr.
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Table IV. Growth inhibitory activity of cefepime and ceftazidime against
resistant isolates selected in vivo
Strain
218 R (CTZ)
219 R (CTZ)
219 R (CPM)
302 R (CTZ)
305 R(CTZ)
Antibiotic
ccfcpiroc
ceftazidime
cefepime
ceftazidime
cefepime
ceftazidime
cefepime
ceftazidime
cefepime
ceftazidime
Growth inhibitory
MIC
0-5
32
4
> 128
2
128
8
32
32
128
concentrations (mg/L)
boundary*
4
50
256
256
128
128
128
128
128
128
'As measured by agar dilution (inoculum: c. 104 cfu per spot).
*As measured by antibiotic gradient containing agar (inoculum: c. 10* cfu per dish).
Second therapeutic exposure
From each group of mice in which resistance emerged during therapy, one or two
resistant isolates were chosen randomly for further studies. Five strains originated from
ceftazidime-treated mice (respectively 218 R (CTZ) I and 2, 219 R (CTZ), 302 R
(CTZ) and 305 R (CTZ)). A sixth strain came from the only cefepime-treated mouse
showing bacterial resistance (219 R (CPM)). Growth inhibitory activity of cefepime
and ceftazidime in vitro against these strains is summarized in Table IV. According to
the agar dilution method with a 104 cfu inoculum, MICs of cefepime always remained
lower than those of ceftazidime, by four-fold against P. aeruginosa and by at least 64-
fold against E. cloacae. With the antibiotic containing gradient agar however, using a
10" cfu inoculum, boundary concentrations increased markedly, becoming similar for
the two antibiotics.
In order to evaluate the therapeutic impact of these diminished in-vitro activities, the
six resistant isolates were inoculated into naive mice, according the same protocol. Ten
untreated mice were used as controls for these experiments, and killed 24 h after
challenge. The macroscopic appearance of peritoneal cavities, and viable counts in the
peritoneal fluid were similar to those found in untreated mice inoculated with cephalo-
sporin-susceptible parent strains. This was a first indication that the resistant isolates
had kept at least part of their initial virulence. Forty-eight mice were inoculated with
one of the resistant isolates and treated with six antibiotic doses. The peritoneal cavity
was sampled one day after challenge to confirm establishment of infection. All
peritoneal fluids yielded growth of the species inoculated. Nine ceftazidime-treated
mice had a peritoneal bacterial population which was more resistant to ceftazidime by
two- to eight-fold, compared to the organism inoculated, (strains 218 R (CTZ)1 and
302 R (CTZ)). All ceftazidime-treated animals were dead by day 3, and most of them
by day 2 after challenge (Table V). After 30 days of observation, cefepime ensured
survival for the six mice infected with 219 R (CTZ), and one out of 12 mice infected
with 218 R (CTZ), but no protection against infections produced by 219 R (CPM) or
the pseudomonas isolates. For comparison purposes, 24 mice were inoculated with
E. cloacae 218S and 219S (susceptible to cephalosporins) and treated as above
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Table V. Therapeutic effects on survival of mice challenged with resistant
isolates and treated by cefepime or ceftazidime (six doses, 50 mg/lcg each, 2 h
apart)
Strain
218S
219S
218 R (CTZ)
219 R (CTZ)
219 R (CPM)
302 R (CTZ)
305 R (CTZ)
Therapy
cefepime
ceftazidime
cefepime
ceftazidime
cefepime
ceftazidime
cefepime
ceftazidime
cefepime
ceftazidime
cefepime
ceftazidime
cefepime
ceftazidime
total
inoculated
6
6
6
6
12
6
6
6
3
3
3
3
3
3
Number of mice
surviving
2
6
5
6
4
3
0
6
5
0
0
0
0
0
0
3
6
3
6
0
1
0
6
0
0
0
0
0
0
0
at day:
30
6
3
6
0
1
0
6
0
0
0
0
0
0
0
(Table V). One month after challenge, the 12 cefepime-treated animals survived,
compared to three out of the 12 mice which were given ceftazidime (P < 005).
Overall, the 22 mice still alive one month after challenge (E. cloacae in all cases) were
apparently healthy. However, at autopsy we found small peritoneal abcesses and
adhesions in seven of them (one ceftazidime-treated, six cefepime treated). Culture of
the pus yielded E. cloacae, with the same pattern of antibiotic activities as the strain
inoculated.
Virulence studies
The LDM of each pair of pre-and post therapy (resistant) strains were less than five-fold
different in all cases, except for the 302 pair, which was approximately one log
Table VL Virulence of parent strains and
cephalosporin-rcsistant mutants of E. cloacae
and P. aeruginosa
Strain JO (cfu)
E. cloacae 21SS 9-5x10*
E. cloacae 219S 1-8x10*
E. cloacae 218 R (CTZ)1 2-0 x 10*
E. cloacae 218 R (CTZ)2 4-9 x 10*
E. cloacae 219 R (CTZ) 2-9 x 10*
E. cloacae 219 R (CPM) 1-0 x 10*
P. aeruginosa 302S 2-7 x 104
P. aeruginosa 3O5S 1-0 x 103
P. aeruginosa 302 R (CTZ) 1-9 x 10*
P. aeruginosa 305 R (CTZ) 2-5 x 103
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different No consistent trend towards an increase or decrease in virulence was noted
after occurrence of resistance (Table VI).
Discussion
After therapy of P. aeruginosa and E. cloacae infections, cefepime produced signifi-
cantly less emergence of resistance than did ceftazidimc, and cefepime therapy
occasionally remained efficient in treating mice infected with resistant E. cloacae
selected by ceftazidime. Several factors could account for this 'dissociated resistance' in
vivo. Host factors were not investigated, and antibiotic concentrations in peritoneal
fluid were similar for the two drugs under study. However differences exist at the
bacterial level. Resistance emerging during 0-lactam therapy of infections caused by
aerobic non-fastidious Gram-negative bacilli is thought to result from the selection of
low frequency mutants characterized by high ^-lactamase production, decreased outer
membrane permeability or both (Marchou ex al., 1987a; Sawai, Yamaguchi & Hiruma,
1988). On antibiotic-gradient containing agars these mutants grew as single colonies
well over the boundary concentration on ceftazidime, but not on cefepime gradients, in
accordance with previous observations demonstrating the cefepime activity against
ceftazidime-resistant bacteria (Vuye & Pick, 1985; Fung-Tome et al., 1989). Recent
studies conducted with E. cloacae 218 (Bellido et al., 1991) showed that the V,,,,,,
reflecting the stability of /Mactamase-substrate complex, was in the same range for
cefepime and 'conventional' third generation cephalosporins; by contrast, the K,,, value
for cefepime was remarkably high, reflecting the previously described low affinity for
the /Mactamase (Hiraoka et al., 1988). In addition, and again in comparison with older
cephalosporins, cefepime was shown to cross the outer membrane more rapidly and
this was so even in a porin F-deficient mutant of E. cloacae 218 (Bellido et al., 1991).
Altogether, in a given time, more cefepime molecules penetrate into the periplasmk
space, avoid the /Mactamase attack and get access to the target molecules, for which
cefepime does not show improved affinity (Bellido et al., 1991).
We have attempted to address the difficult question of the significance of the
resistance emerging during therapy. Clinically, this resistance is associated with thera-
peutic failure in about half of the cases (Milatovic & Braveny, 1987). The time course
of viable counts in peritoneal fluid from animals treated by either antibiotic showed
that, whether or not resistance occurred, the bacterial populations remained similar, at
least for the first 8 h. A rather dramatic antibacterial effect was seen in all cases, which
may correspond to the elimination of the susceptible population. The resistant mutants,
which form a small minority within this population, grew at the same rate as their
susceptible counterparts in broth medium (data not shown). So we assume that during
the first hours following initiation of therapy, the lack of visible resistant cells in viable
counts was due to their small number at the time of challenge. As an example, if the
frequency of resistant cells was one in a million, a challenge inoculum of 10s cfu would
have provided only 100 resistant cells. So resistance is not necessarily synonymous with
therapeutic failure probably because, in some cases, the host defence can eliminate such
small number of bacteria. However, despite the important structural and functional
changes associated with the mutation to resistance (derepressed /Mactamase produc-
tion, which represents a significant expense of energy, and altered permeability with
possible consequences on bacterial uptake of various substances) the resistant mutants
kept their initial virulence as determined here by the LDg, assays. They also resisted
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treatment with their selective agents in vivo, leading to lethal therapeutic failure. These
observations contrast with other examples where antibiotic resistance is associated with
lower virulence such as gentamicin resistance in S. aureus (Musher et at., 1977;
Pelletier, Richardson & Feist, 1979) or P. aeruginosa (Keys & Washington, 1977;
Khakoo & Kluge, 1978), isonazid resistance in Mycobacterium tuberculosis (Middle-
brook, 1957) or antibiotic resistance in Neisseria gonorrhoeae (Stollerman, 1978).
Therapeutic failure occurring when the pathogen is classified as susceptible to the
antibiotic administered in vitro represents a very major error of susceptibility testing
which has been seen with recent broad spectrum /Mactam compounds used for treating
non-fastidious Gram-negative aerobic bacteria like E. cloacae and P. aeruginosa
(Sanders, 1984). In this setting, both animal and clinical studies (Michea-Hamzehpour
et at., 1989) have shown that MICs (or their equivalent in disc diffusion techniques)
were poor predictors of emergence of resistance, at least when the strains were 'so-
called' susceptible. This is likely to be due to the bacterial inoculum used in the testing
procedures (typically 10* or 105 cfu, and less in microtechniques) compared with the
scarce number of mutants associated with resistance (often less than one in 105 cells).
Using a higher inoculum (10* cfu), the antibiotic gradient method described here
allowed detection of these mutants. Resistance occurred in the mice only when the
difference in /Mactam inhibitory concentrations between the wild type cells and the
mutants was at least five-fold, as determined by the ratio no-growth concentration/
boundary concentration. No resistance was observed when the two subpopulations
were relatively similar (less than four-fold difference). By contrast, as shown previously
(Michea-Hamzehpour & Pechere, 1989), the presence and frequency of resistant
mutants, and even the level of their resistance in vitro to the /Mactam given to the
animal, did not predict faithfully further development of resistance in vivo. The links
which are likely to exist between these observations and pharmacokinetics obviously
deserve further studies.
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